Download PDF
Thromb Haemost 1963; 09(01): 090-101
DOI: 10.1055/s-0038-1654963
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Relation of Factors XII, XI, and IX to Hypercoagulable States[*] [**]

With the technical assistance of Jacqueline D. La Croix and V. Jane Cranney
Duncan P Thomas
1   Medical Research Department of the Yamins Research Laboratory, Beth Israel Hospital, and the Department of Medicine, Harvard Medical School
,
Stanford Wessler
1   Medical Research Department of the Yamins Research Laboratory, Beth Israel Hospital, and the Department of Medicine, Harvard Medical School
,
Stanley M Reimer
1   Medical Research Department of the Yamins Research Laboratory, Beth Israel Hospital, and the Department of Medicine, Harvard Medical School
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

    Permissions and Reprints

Summary

Evidence has been obtained in rabbits that the reduction of the silicone whole blood clotting time to the normal glass range reflects a hypercoagulable state attributable to circulating activated factors XII and XI. The potential clinical implications of these findings are discussed.

* This study was supported by research grants H-1027 and HTS-5235 from the National Institutes of Health and by a grant-in-aid from the American Heart Association.


** Presented in part before American Physiological Society, Atlantic City, New Jersey, April 15, 1962.


 

  • References

  • 1 Wessler S. Studies in intravascular coagulation. III. The pathogenesis of seruminduced venous thrombosis. J. clin. Invest. 34: 647 1955;
    CrossrefPubMedGoogle Scholar
  • 2 Wessler S, Reimer S. M. The role of human coagulation factors in serum-induced thrombosis. J. clin. Invest. 39: 262 1960;
    CrossrefPubMedGoogle Scholar
  • 3 Reimer S. M, Wessler S, Deykin D. Serum thrombotic accelerator (STA) activity: its relation to the first phase of clotting. Proc. Soc. exp. Biol. (N. Y) 105: 438 1960;
    CrossrefPubMedGoogle Scholar
  • 4 Wessler S, Freiman D. G, Suyemoto J, Reimer S. M. Serum thrombotic accelerator (STA) activity: a possible key to massive venous thromboembolism in man. Trans. Ass. Amer. Phys. 74: 111 1961;
    PubMedGoogle Scholar
  • 5 Henderson E. S, Rapaport S. I. Evidence that Activation Product causes serum-induced thrombosis. Clin. Res. 09: 160 1961;
    PubMedGoogle Scholar
  • 6 Didisheim P, Vandervoort R. L. E, Rytting J. E. Formation of serum thrombotic accelerator (STA) in plasma. Clin. Res. 10: 77 1962;
    PubMedGoogle Scholar
  • 7 Wessler S, Reiner L, Freiman D. G, Reimer S. M, Lertzman M. Serum-induced thrombosis: Studies of its induction and evolution under controlled conditions in vivo. Circulation 20: 864 1959;
    CrossrefPubMedGoogle Scholar
  • 8 Rees H. M, Ecker E. E. An improved method for counting blood platelets. J. Amer. med. Ass. 80: 621 1923;
    PubMedGoogle Scholar
  • 9 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path. 19: 471 1949;
    PubMedGoogle Scholar
  • 10 Wessler S, Reimer S. M, Sheps M. C. Biologie assay of a thrombosisinducing activity in human serum. J. appl. Physiol. 14: 943 1959;
    CrossrefPubMedGoogle Scholar
  • 11 Lee R. I, White P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sci. 145: 495 1913;
    CrossrefPubMedGoogle Scholar
  • 12 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. (Suppl) 11: 37 1959;
    CrossrefPubMedGoogle Scholar
  • 13 Wartelle O. Les facteurs prothromboplastiques du sang de poule et de quelques mammifères. Thèse, Travail du Centre National de Transfusion, Sanguine, Paris 1959
    PubMedGoogle Scholar
  • 14 Thompson J. H, Spittel J. A, Pascuzzi C. A, Owen C. A. Laboratory and genetic observations in another family with the Hageman trait. Proc. Mayo Clin. 35: 421 1960;
    PubMedGoogle Scholar
  • 15 Fanti P. A comparative study of blood coagulation in vertebrates. Aust. J. exp. Biol, med. Sci. 39: 404 1961;
    PubMedGoogle Scholar
  • 16 Soulier J. P. Our present knowledge of PTA factor. Thrombos. Diathes. haemorrh. Suppl. ad IV: 123 1960;
    PubMedGoogle Scholar
  • 17 Henderson E. S, Rapaport S. The thrombotic activity of activation product. J. clin. Invest. 41: 235 1962;
    CrossrefPubMedGoogle Scholar
  • 18 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest. 40: 803 1961;
    CrossrefPubMedGoogle Scholar
  • 19 Ratnoff O. D. The activation of Christmas factor by activated plasma thromboplastin antecedent. J. clin. Invest. 40: 1074 1961;
    PubMedGoogle Scholar
  • 20 Ferguson J. H, Wilson E. G, Iatridis S. G, Rierson H. A, Johnston B. R. Enzymes and blood clotting. I. Trypsin as an accessory factor. J. clin. Invest. 39: 1942 1960;
    CrossrefPubMedGoogle Scholar
  • 21 Wessler S, Cohen S, Fleischner F. G. The temporary thrombotic state. Application of this concept to the therapy of recurrent thromboembolism, with bactériologie and roentgenologic considerations in the differential diagnosis of pulmonary infarction and pneumonia. New Engl. J. Med. 254: 413 1956;
    CrossrefPubMedGoogle Scholar
  • 22 Tillett W. S, Johnson A. Personal communication.
    PubMedGoogle Scholar